Pneumococcal 20-valent conjugate vaccine Side Effects
Medically reviewed by Drugs.com. Last updated on Jun 12, 2023.
Applies to pneumococcal 20-valent conjugate vaccine: intramuscular suspension.
Serious side effects
Along with its needed effects, pneumococcal 20-valent conjugate vaccine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking pneumococcal 20-valent conjugate vaccine:
More common
Incidence not known
- Blistering, peeling, or loosening of the skin
- chest tightness
- chills
- cough
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- red, irritated eyes
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- swollen, painful, or tender lymph glands in the neck, armpit, or groin
- trouble breathing
- unusual tiredness or weakness
Other side effects
Some side effects of pneumococcal 20-valent conjugate vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- difficulty in moving
- headache
- muscle pain or stiffness
- pain in the joints
For Healthcare Professionals
Applies to pneumococcal 20-valent conjugate vaccine: intramuscular suspension.
General
The most common adverse reactions reported for most adults were pain at the injection site, muscle pain, fatigue, headache, arthralgia, and injection site swelling.[Ref]
Cardiovascular
Postmarketing reports: Pediatric cyanosis, pediatric pallor[Ref]
Dermatologic
Uncommon (0.1% to 1%): Angioedema, rash
Postmarketing reports: Angioneurotic edema, erythema multiforme[Ref]
Gastrointestinal
Uncommon (0.1% to 1%): Diarrhea, nausea, vomiting[Ref]
Hematologic
Postmarketing reports: Lymphadenopathy at injection site[Ref]
Hypersensitivity
Uncommon (0.1% to 1%): Hypersensitivity reaction
Postmarketing reports: Anaphylactic/anaphylactoid reaction (including shock)[Ref]
Local
Very common (10% or more): Injection site pain (up to 81.2%), injection site swelling (up to 16.4%), injection site redness (up to 25.5%)
Postmarketing reports: Vaccination-site dermatitis, vaccination-site pruritus, vaccination-site urticaria[Ref]
Metabolic
Very common (10% or more): Decreased appetite among infants (up to 26.4%)[Ref]
Musculoskeletal
Very common (10% or more): Muscle pain (up to 66.6%), joint pain (up to 13.4%)
Frequency not reported: Limitation of arm movement, arthralgia[Ref]
Nervous system
Very common (10% or more): Headache (up to 38.8%), drowsiness among infants (up to 67.2%)
Frequency not reported: Seizures
Postmarketing reports: Pediatric hypotonia[Ref]
Other
Very common (10% or more): Fatigue (up to 42.7%), fever in infants (up to 17.3%)
Common (1% to 10%): Pyrexia
Uncommon (0.1% to 1%): Chills[Ref]
Psychiatric
Very common (10% or more): Irritability among infants (up to 70.9%)[Ref]
Respiratory
Uncommon (0.1% to 1%): Bronchospasm, dyspnea
Postmarketing reports: Pediatric apnea[Ref]
More about pneumococcal 20-valent conjugate vaccine
- Check interactions
- Compare alternatives
- Reviews (22)
- Dosage information
- During pregnancy
- Drug class: bacterial vaccines
- En español
Patient resources
- Pneumococcal 20-valent conjugate vaccine drug information
- Pneumococcal 20-valent conjugate vaccine (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Prevnar 20 (pneumococcal 20-valent conjugate vaccine). Pfizer Inc. 2023.
2. Product Information. Prevenar-20 (pneumococcal 20-valent conjugate vaccine). Pfizer Australia Pty Ltd. 2022;pfpprvni11222.
3. Product Information. Apexxnar (pneumococcal 20-valent conjugate vaccine). Pfizer Ltd. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.